Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single center experience
Full text
Figure
Related documents
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results
CUAJ ? Consensus Statement Mason et al KCRNC consensus Cytoreductive nephrectomy for mRCC Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of
Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC
Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer. OncoTargets
We present an overview of three patients diagnosed as having renal cell carcinoma with malignant intravascular thrombus requiring radical nephrectomy combined with inferior vena
We found regional lymph node metastasis por- tends a particularly poor prognosis after radical nephrectomy with tumor thrombectomy. In fact, patients with isolated lymph node
Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a
Figure 3: Comparison of progression-free survival and overall survival between cytoreductive nephrectomy, renal embolization and no invasive renal treatment groups, stratified by